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•  The avai lable evidence supports the pharmacokinetics and 
pharmacodynamics bioequivalence of the SC and IV administration of TZ. 
•  TZ subcutaneously is more cost-effective and more convenient for patients.  
•  Therefore, the SC route is currently the best option for the administration of 
TZ in the treatment of HER2-positive BC and its adoption as the standard 
route of administration is probably a matter of time. 
•  Breast cancer (BC) is the most common cancer in women worldwide; it has an 
unquestionable negative impact on the public health of the modern societies. 
•  Trastuzumab (TZ), a recombinant antibody targeting the human epidermal 
growth factor receptor (HER) 2, was the first biological drug approved for the 
treatment of HER2-positive BC and remains the gold-standard for this 
indication.  
•  Currently, TZ is available in intravenous (IV) and subcutaneous (SC) 
formulations; clinicians are routinely confronted with the difficult of selecting 
the best administration route for this drug .  
•  This work aims to clarify which administration route is preferable for TZ in 
the treatment of BC.  
Conclusions 
Background and objective 
Figure 1: Structure of the humanised monoclonal antibody 
trastuzumab (TZ)  
•  Literature review. PubMed database was searched for clinical studies 
published in the last five years, using combinations of the keywords: “breast 
cancer”, "intravenous trastuzumab" and "subcutaneous trastuzumab”. 
 
 
Results 
•  IV doses of TZ should be adjusted to the body weight whilst the SC 
formulation has an approved dosing schedule of 600 mg every three weeks, 
irrespective of patients’ body weight [1]. Actually, several studies have 
suggested that the body size does not significantly influence the 
pharmacokinetics of TZ [2-4].  
•  The SC administration does not require a loading dose, given that the first 
dose results in therapeutic concentrations [2-4]. 
•  Two recently published studies on the comparison of the two formulations 
deserve attention: the  HannaH study [5] and the PreffHer study [7]. 
 
HannaH study  
•  Randomised phase 3 study with the aim of demonstrating the non-inferiority 
of SC TZ in relation to IV TZ at the pharmacokinetics and pharmacodynamics 
level. The study enrolled 596 patients with HER2-positive BC that received SC 
or IV TZ randomly at every three weeks. 
•  Mean serum concentrations achieved for IV and SC groups were similar (1st 
cycle: 34,5 µg/ml versus 32,7 µg/ml; 3rd cycle: 45,0 µg/ml versus 48,4 µg/
ml, respectively). 
•  However, it was verified a higher fluctuation index for SC TZ: 
o Mean Cmin was higher in the 8th and 13th cycle for patients treated with SC TZ 
(78,7 µg/mL and 90,4 µg/mL respectively) compared to IV TZ (57,8 µg/mL and 
62,1 µg/mL respectively); 
o Mean Cmax was lower in the group of SC TZ (149 µg/mL versus 221 µg/mL). 
•  Steady state concentrations were first achieved for IV TZ (8th cycle versus 
13th cycle). 
•  The SC formulation was non-inferior with respect to the primary 
pharmacokinetics endpoint, the mean Cmin measured after seven cycles. 
•  There was comparable efficacy for the two routes, as shown by the 
proportion of patients who achieved pathological complete response: 118 out 
of 260 (SC TZ) and 107 out of 263 (IV TZ). 
•  No significant differences were observed in the safety profile, although the 
subcutaneously-treated group reported more adverse effects (21% versus 
12%), particularly infections and infestations. 
 
  
 
 
 
PreffHer study  
•  A randomized study that evaluated the patient preference between the two 
TZ administration routes in 248 patients. 
•  92% of the patients chose the SC option as the preferred administration route, 
due to time saving, less pain/discomfort, ease of administration and more 
convenience. 
•  The remaining 8% of patients justified to prefer the IV route mainly due to 
the less pain, bruising and irritation associated to the administration. 
Route Intravenous (IV) Subcutaneous (SC) 
Maintenance dose 
•  Three weekly schedule- 6mg/
kg 
•  Weekly schedule – 2 mg/kg 
Fixed dose of 600 mg every 
three weeks 
Loading dose 
•  Three weekly schedule – 8 
mg/kg 
•  Weekly schedule - 4mg/kg 
Not required  
Time of administration 
Loading dose: 90 minutes 
Following doses: 30 minutes 
2-5 minutes 
Pharmacokinetics profile  Bioequivalent 
Efficacy and safety 
profile 
Similar 
The SC formulation contains recombinant human hyaluronidase to overcome 
absorption barriers, which reduces the administration duration and removes 
the need to establish intravenous access, thus improving the overall 
convenience of TZ administration [5]. 	  
Table 1: Overview of the IV SC and SC routes for trastuzumab (TZ)  
